Drug intelligence / Profile preview

Evolysse Lips

Development stage: Preclinical
Lead developer: Symatese
Administration: Intradermal, Subcutaneous

Overview

Evolysse Lips is an injectable hyaluronic acid (HA) gel dermal filler developed by Evolus, Inc. in partnership with Symatese. It is part of the Evolysse™ product line, which utilizes proprietary Cold-X™ technology designed to preserve the natural structure of the HA molecule, aiming for natural-looking and long-lasting results. Specifically indicated for lip augmentation and enhancement, the product is currently in clinical development with a targeted U.S. commercial launch in 2027. As a dermal filler, it functions by restoring tissue volume through the humectant properties of hyaluronic acid.

Brand names: Evolysse Lips
Other names: Evolysse™ Lips

Beyond the preview

Go deeper on Evolysse Lips.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evolysse Lips.

Explore the full profile